DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Information source: Allergan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glaucoma; Ocular Hypertension

Intervention: bimatoprost 0.01% (Drug); travoprost 0.004% (Drug); timolol 0.5% (Drug); hypromellose 0.3% (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan


This efficacy and safety study will evaluate LUMIGAN® .01 (bimatoprost 0. 01%) alone compared to TRAVATAN Z® (travoprost 0. 004%) and TIMOLOL GFS, 0. 5% (timolol 0. 5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: Intraocular Pressure (IOP) in the Study Eye


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Ocular hypertension or glaucoma that requires treatment with medication

- Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes

Exclusion Criteria:

- History of LASIK, LASEK, RK, and/or PRK in the study eye(s)

- History of any intraocular surgery or glaucoma laser surgery in the study eye(s)

within 3 months

- Use of topical, periorbital, intravitreal or systemic steroid within 3 months or

expected use during the course of study

Locations and Contacts

Racine, Wisconsin, United States
Additional Information

Starting date: April 2014
Last updated: December 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017